Avicanna Reports Full Year 2023 Audited Financial Results

$16.8M in Revenue, representing an increase of 314% from 2022
$6.7M Consolidated gross Profit, representing an increase of 500% from 2022

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce year end 2023 results and audited financial statements.

Read more at globenewswire.com